Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders.

Cell reports. Medicine·2022
Same author

Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration.

Neurology·2021
Same author

Brain volumetric deficits in MAPT mutation carriers: a multisite study.

Annals of clinical and translational neurology·2020
Same author

Constructing Connectome Atlas by Graph Laplacian Learning.

Neuroinformatics·2020
Same author

Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2020
Same author

Apathy rating scores and β-amyloidopathy in patients with Parkinson disease at risk for cognitive decline.

Neurology·2019

Related Experiment Video

Updated: Jun 3, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Dementia in Parkinson's disease.

Avrom L Kurtz1, Daniel I Kaufer

  • 1Department of Neurology, CB 7025, The University of North Carolina at Chapel Hill, 3129 Physician Office Building, Chapel Hill, NC, 27599, USA, kurtza@neurology.unc.edu.

Current Treatment Options in Neurology
|April 5, 2011
PubMed
Summary

Managing dementia in Parkinson's disease (PD) requires careful medication selection. Minimizing anticholinergic and antipsychotic drugs is crucial, while cholinesterase inhibitors and memantine offer cognitive benefits for Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD).

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Area of Science:

  • Neurology
  • Geriatrics
  • Pharmacology

Background:

  • Dementia in Parkinson's disease presents as Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD).
  • Anticholinergic and antipsychotic medications pose significant risks for cognitive and motor adverse effects in these patients.
  • Neuroleptic sensitivity, a severe psychomotor reaction, affects up to 50% of individuals with PDD or DLB, particularly with potent dopamine-blocking agents.

Purpose of the Study:

  • To provide guidance on managing the complex symptoms of dementia in Parkinson's disease.
  • To highlight medication risks and recommend safer alternatives for cognitive, psychiatric, and motor symptoms.
  • To address associated features like sleep disorders and orthostatic hypotension.

Main Methods:

  • Review of current pharmacological approaches for managing dementia in Parkinson's disease.
  • Analysis of adverse effects associated with common psychotropic and antiparkinsonian medications.
  • Evaluation of evidence for cholinesterase inhibitors, memantine, and other agents in treating cognitive and psychiatric symptoms.
  • Consideration of non-pharmacological and pharmacological strategies for associated non-motor symptoms.

Main Results:

  • Anticholinergic and antipsychotic drugs should be minimized or avoided due to high risks.
  • Cholinesterase inhibitors demonstrate efficacy for cognitive and psychiatric symptoms in DLB and PDD.
  • Memantine may offer variable cognitive benefits, particularly in PDD.
  • Carbidopa/levodopa is the preferred treatment for motor signs with cognitive impairment, avoiding dopamine agonists.
  • Quetiapine or clozapine may be used for severe psychotic symptoms.
  • Management strategies for excessive daytime sleepiness, REM sleep behavior disorder, and orthostatic hypotension are discussed.

Conclusions:

  • Careful medication management is essential to optimize treatment and minimize adverse events in Parkinson's disease dementia.
  • Cholinesterase inhibitors and memantine represent valuable therapeutic options for cognitive and psychiatric symptoms.
  • Tailored approaches are necessary for managing non-motor symptoms associated with PDD and DLB.